Thymosin alpha 1 in liver failure: an open-label randomized study
Seventy-three patients with hepatitis-B-related acute-on-chronic liver failure received standard care with or without thymosin alpha 1.
Clinical trialPaper year: 2026Thymosin alpha 1
01 / DESIGN
What was studied?
Seventy-three patients with hepatitis-B-related acute-on-chronic liver failure received standard care with or without thymosin alpha 1.
02 / FINDINGS
What did the researchers report?
The study reported higher transplant-free survival alongside changes in regulatory T-cell subsets and the time course of inflammatory markers.
03 / INTERPRETATION
What are the limits?
The trial was small and open-label in a severe, specific condition. Immune correlations do not prove which pathway produced the outcome, and broader claims require replication.
Original editorial summary by Sulan Peptide. Based on the source abstract; consult the full paper for methods, analyses, funding and disclosures.
RESEARCH CONTEXT
These are original reading notes on published studies, not product testimonials. Clinical studies used their own pharmaceutical formulations and protocols; their findings do not establish the safety, efficacy or equivalence of materials in our catalog. No personal-use or treatment guidance is provided.
Related catalog navigation only. The supplied material is not established as equivalent to the study product, and the paper does not certify a supply batch.
